Latest News

Credit: Juan Gärtner | stock.adobe.com
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial

February 13th 2025

The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.

 Implementing Diversity, Equity, and Inclusion in Drug Development
Implementing Diversity, Equity, and Inclusion in Drug Development

February 13th 2025

SCOPE Summit 2025: Implementing Decentralized Elements
SCOPE Summit 2025: Implementing Decentralized Elements

February 13th 2025

Prioritizing Efficiency
Prioritizing Efficiency

February 12th 2025

SCOPE Summit 2025: Addressing Challenges in Clinical Data Management and Analytics
SCOPE Summit 2025: Addressing Challenges in Clinical Data Management and Analytics

February 12th 2025

Applied Clinical Trials December 2024

Check out the latest features and columns!

Check out the latest features and columns!

Conference Coverage

View All
SCOPE Summit 2025: Implementing Decentralized Elements
SCOPE Summit 2025: Implementing Decentralized Elements

February 13th 2025

SCOPE Summit 2025: Addressing Challenges in Clinical Data Management and Analytics
SCOPE Summit 2025: Addressing Challenges in Clinical Data Management and Analytics

February 12th 2025

SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity

February 12th 2025

SCOPE Summit 2025: The Importance of Language in Patient Engagement
SCOPE Summit 2025: The Importance of Language in Patient Engagement

February 11th 2025

Latest Videos
Podcasts
© Alex from the Rock - © Alex from the Rock - stock.adobe.com

All News

© 2025 MJH Life Sciences

All rights reserved.